Wall Street brokerages expect that Glaukos Corp (NYSE:GKOS) will report $40.78 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Glaukos’ earnings. The highest sales estimate is $41.70 million and the lowest is $39.63 million. Glaukos posted sales of $41.29 million during the same quarter last year, which suggests a negative year over year growth rate of 1.2%. The company is expected to report its next earnings results on Wednesday, August 1st.
According to Zacks, analysts expect that Glaukos will report full-year sales of $163.80 million for the current fiscal year, with estimates ranging from $163.10 million to $164.90 million. For the next year, analysts anticipate that the company will report sales of $184.65 million per share, with estimates ranging from $177.02 million to $193.40 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Glaukos.
Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, May 9th. The medical instruments supplier reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02. Glaukos had a negative net margin of 2.25% and a positive return on equity of 1.22%. The company had revenue of $40.10 million for the quarter, compared to analyst estimates of $37.63 million. During the same quarter last year, the business earned $0.02 earnings per share. Glaukos’s revenue was up 11.7% compared to the same quarter last year.
Shares of NYSE:GKOS opened at $43.83 on Tuesday. Glaukos has a 52 week low of $23.08 and a 52 week high of $44.76. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of 860.40 and a beta of 1.08.
In related news, COO Chris M. Calcaterra sold 8,771 shares of the firm’s stock in a transaction that occurred on Friday, June 15th. The shares were sold at an average price of $44.01, for a total transaction of $386,011.71. Following the transaction, the chief operating officer now owns 248,771 shares in the company, valued at $10,948,411.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 11.60% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in Glaukos by 2.4% during the first quarter. BlackRock Inc. now owns 2,004,379 shares of the medical instruments supplier’s stock worth $61,795,000 after buying an additional 47,265 shares in the last quarter. William Blair Investment Management LLC boosted its holdings in Glaukos by 7.5% during the fourth quarter. William Blair Investment Management LLC now owns 1,979,960 shares of the medical instruments supplier’s stock worth $50,786,000 after buying an additional 137,969 shares in the last quarter. Baillie Gifford & Co. boosted its holdings in Glaukos by 15.4% during the first quarter. Baillie Gifford & Co. now owns 1,119,613 shares of the medical instruments supplier’s stock worth $34,518,000 after buying an additional 149,334 shares in the last quarter. Federated Investors Inc. PA boosted its holdings in Glaukos by 75.7% during the first quarter. Federated Investors Inc. PA now owns 790,750 shares of the medical instruments supplier’s stock worth $24,379,000 after buying an additional 340,696 shares in the last quarter. Finally, Cortina Asset Management LLC bought a new stake in Glaukos during the first quarter worth approximately $20,644,000.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.